Lexeo Therapeutics Inc. (LXEO)
NASDAQ: LXEOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LXEO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $245.05M
- EPS (TTM)
- -$1.13
- Dividend yield
- None
- 52-week range
- 2.55 – 10.99
- Day range
- 2.89 – 3.25
- Volume / Avg
- 1.80M / 1.98M
- Beta
- —
- Shares outstanding
- 82.79M
52-week range
LXEO stock today
Lexeo Therapeutics (LXEO) closed at $2.96 on Nov 20, up 0.34% (+$0.01), versus the S&P 500's 3.70% decline. At this level, LXEO sits near the bottom of its 52-week range of $2.55 to $10.99: 73.1% below the high, set on Dec 23, 2025 and 16.1% above the low. LXEO is down 70.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.3%.
Lexeo Therapeutics has posted a net loss over the last twelve months (EPS of -$1.13), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lexeo Therapeutics
Company profileLexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. R. Nolan Townsend M.B.A.
- Headquarters
- New York, NY
- Employees
- 68
- IPO year
- 2023
- Website
- lexeotx.com
Financial highlights
Full financialsLexeo Therapeutics reported a net loss of $100.0 million, compared with a loss of $98.3 million a year earlier. Diluted earnings per share came in at -$1.86.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | $654.00K |
| Growth | — | — | — | — |
| Net income | $-100.00M | $-98.33M | $-66.39M | $-59.28M |
| EPS (diluted) | $-1.86 | $-3.09 | $-12.40 | $-36.36 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$25.11+748.31%
- Strong buy 2
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.43 vs $-0.33
- Surprise
- -30.30%
LXEO news
All LXEO news- Lexeo Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Positive Interim Phase I/II Data for LX2020Nasdaq
- Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026GlobeNewswire
- Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMGlobeNewswire
- Lexeo Therapeutics to Participate in the Chardan Healthcare ConferenceGlobeNewswire
Lexeo Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs LXEO |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs LXEO |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs LXEO |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs LXEO |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs LXEO |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs LXEO |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs LXEO |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs LXEO |
Indexes, lists and sector
Lexeo Therapeutics stock FAQ
What is Lexeo Therapeutics's stock price today?
LXEO last traded at $2.96 as of Nov 20, 4:00 PM EST, up 0.34% on the day. Prices are delayed at least 15 minutes.
Who is Lexeo Therapeutics's CEO?
Mr. R. Nolan Townsend M.B.A. is the chief executive officer of Lexeo Therapeutics Inc., which has about 68 employees.
What is the LXEO 52-week high?
The 52-week high for LXEO is $10.99 and the 52-week low is $2.55. The stock is currently 73.1% below its high.